Clinical trials: Patients with Multiple Sclerosis
Fatigue, Multiple Sclerosis
Continuous Positive Airway Pressure (CPAP) for Fatigue in Patients With Multiple Sclerosis (MS) and Obstructive Sleep Apnea (OSA)
Fatigue is a symptom present in 76 to 92% of people with multiple sclerosis (MS). Fatigue is usually described as an overwhelming sense of tiredness, lack of energy, and feeling of exhaustion which is different from sleepiness.
- Conditions
- Fatigue, Multiple Sclerosis, Sleep Apnea
- Trial name
- NCT01563900
- Testing
- Auto-titration CPAP
- Where
- United States
- Sponsor
- Northwestern University
Multiple Sclerosis
12-week Study to Evaluate RebiSmart™ Suitability for Self Injection in Relapsing Multiple Sclerosis.
The Electronic Device - The RebiSmart™ is an electronic injection device that is being studied for the delivery of Merck Serono's Rebif® New Formulation.
- Trial name
- NCT00735007
- Testing
- Rebif® New Formulation (RNF) using RebiSmartTM
- Where
- 6 sites in United States, Canada and 4 more
- Volunteers
- 106 people
- Sponsor
- EMD Serono
Multiple Sclerosis, Relapsing
Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab
Open-label, prospective, single-arm, multi-center study to assess disease activity and biomarker of neuronal damage in minority patients (self-identified Black or African American (AA) and Hispanic/Latino (HA) patients with…
- Trial name
- NCT04377555
- Testing
- Ocrelizumab
- Where
- 28 sites in United States, Kenya and 1 more
- Volunteers
- 179 people
- Sponsor
- Genentech, Inc.
Multiple Sclerosis, Muscle Spasticity
Intermittent Theta-Burst Stimulation for Lower-Limb Spasticity and Pain in Multiple Sclerosis
Spasticity and neuropathic pain are frequent and disabling symptoms of multiple sclerosis. Intermittent theta-burst stimulation (iTBS) is a non-invasive neuromodulation technique that may modulate cortical and corticospinal…
- Conditions
- Multiple Sclerosis, Muscle Spasticity, Neuropathic Pain
- Trial name
- TMS-SPASMS (NCT07786506)
- Testing
- Active Intermittent Theta-Burst Stimulation (iTBS)
- Where
- Slovakia
- Volunteers
- 40 people
- Sponsor
- Comenius University
Depression, Relapsing-remitting Multiple Sclerosis
Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
This is a prospective, multi-center, open-label study in Relapsing-remitting Multiple Sclerosis (RRMS) patients with mild to moderate depression treated with selected serotonin reuptake inhibitors (SSRI) or serotonin and…
- Trial name
- REGAIN (NCT01436643)
- Testing
- Venlafaxine, Fluoxetine, Citalopram
- Where
- 25 sites in Germany
- Volunteers
- 54 people
- Sponsor
- Novartis Pharmaceuticals
Relapsing Multiple Sclerosis
Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab
The study provided efficacy, safety, and pharmacokinetics (PK) data for patients with relapsing multiple sclerosis (RMS) in Japan and the other countries
- Trial name
- NCT03249714
- Testing
- Ofatumumab
- Where
- 14 sites in Japan, Russia
- Volunteers
- 64 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Retrospective Observational Study About Long-term Effect of Fampridine in Patients With Multiple Sclerosis
Mobility problems in multiple sclerosis (MS) is a frequent symptom. It might appear in almost 93% of patients in the first 15 years of the disease, being a clear problem for their normal living.
- Trial name
- RETROFAM (NCT02966808)
- Testing
- cognitive and behavioural questionnaires
- Where
- Spain
- Volunteers
- 50 people
- Sponsor
- Hospital General Universitario Gregorio Marañon
Relapsing Remitting Multiple Sclerosis (RRMS), Malnutrition or Risk of Malnutrition
The Prevalance of Malnutrition and Its Association With Disability in Patients With Relapsing-Remitting Multiple Sclerosis
This prospective observational study aims to determine the prevalence of malnutrition in patients with relapsing-remitting multiple sclerosis and to evaluate its association with disability.
- Trial name
- NCT07497126
- Where
- Turkey (Türkiye)
- Volunteers
- 169 people, healthy volunteers welcome
- Sponsor
- Antalya Training and Research Hospital
Multiple Sclerosis, Relapsing-Remitting
A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS
STUDY OBJECTIVES: Primary Objective: Assessment of treatment safety based on incidence of any treatment emergent/treatment associated adverse events prior to discharge and at 1, 3, 6 and 12 months post treatment.
- Trial name
- NCT02418325
- Testing
- Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells, Liberation therapy
- Where
- Trinidad and Tobago
- Volunteers
- 69 people
- Sponsor
- Genesis Limited
Multiple Sclerosis
A Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of RPH-035 and Ocrevus® in Patients With Relapsing-remitting or Secondary Progressive Multiple Sclerosis With Exacerbations
The study goal is to establish the equivalence of pharmacokinetic (PK) properties, as well as the comparability of safety, immunogenicity (IG) and pharmacodynamics (PD) of the drug product RPH-035 (R-Pharm JSC, Russia) in…
- Trial name
- NCT07597668
- Testing
- RPH-035, Ocrevus®
- Where
- 23 sites in Russia
- Volunteers
- 180 people
- Sponsor
- R-Pharm
Multiple Sclerosis
Efficacy of COVID-19 Vaccination in Patients With Multiple Sclerosis Treated With Immune Modulating Medication
The primary objective is to determine whether the use of immunomodulating medications have an impact on the ability to mount and sustain an immune response to SARS-CoV-2 spike protein following mRNA vaccination in patients with…
- Trial name
- NCT04796584
- Testing
- Analysis of cell-mediated and antibody-mediated immunity to SARS-CoV-2 virus
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Providence Health & Services
Multiple Sclerosis, Psychological Distress
The Impact of Positive Mental Training in Multiple Sclerosis
Depression and anxiety are common in MS and often go untreated. Even symptoms which do not meet the threshold for a psychiatric diagnosis can have a significant impact on quality of life.
- Trial name
- PosMTMS (NCT02524093)
- Testing
- Positive Mental Training, treatment as usual
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- University of Edinburgh
Relapsing Remitting Multiple Sclerosis, Progressive Multiple Sclerosis
Identification of Retinal Perivascular Inflammation in Patients With Multiple Sclerosis Using Adaptive Optics (RETIMUS)
Using a technique called adaptive optics imaging applied on retina, investigators aim to gain access to vascular changes that could occur early in the course of Multiple Sclerosis (MS) and which could reflect vascular changes…
- Conditions
- Relapsing Remitting Multiple Sclerosis, Progressive Multiple Sclerosis, Optic Neuritis, Eye Diseases
- Trial name
- RETIMUS (NCT04289909)
- Testing
- Adaptive Optics Ophthalmoscopy (AOO)
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Multiple Sclerosis
Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of ACT-128800 in Patients With Relapsing-remitting Multiple Sclerosis
This study will assess the efficacy, safety, and tolerability of ACT-128800 in patients with relapsing-remitting multiple sclerosis.
- Trial name
- NCT01006265
- Testing
- ACT-128800 Dose 1, ACT-128800 Dose 2, ACT-128800 Dose 3
- Where
- 115 sites in United States, Australia and 21 more
- Volunteers
- 464 people
- Sponsor
- Actelion
Amyotrophic Lateral Sclerosis, Motor Neuron Disease
Phase 1 Dose Escalation and PK Study of Cu(II)ATSM in ALS/MND
Multicenter, open-label , single and multiple dose-escalation and pharmacokinetic study
- Trial name
- NCT02870634
- Testing
- Cu(II)ATSM
- Where
- 2 sites in Australia
- Volunteers
- 50 people
- Sponsor
- Collaborative Medicinal Development Pty Limited
Multiple Sclerosis (MS)
Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2)-Related Multiple Sclerosis (MS) Vaccination Study
The primary objective of this study is to document immunization status of MS participants after SARS-CoV-2-vaccinations and to evaluate possible effects of disease modifying therapy (DMTs) on the immune status.
- Trial name
- NCT05197699
- Where
- 12 sites in Germany
- Volunteers
- 160 people
- Sponsor
- Biogen
Multiple Sclerosis (MS) - Relapsing-remitting
The Effect of Metformin As an Adjuvant Therapy on Immunological Parameters in Egyptian Patients with RRMS: a Pilot Study
This pilot study aims to investigate the tolerability and feasibility of using metformin as an adjuvant treatment for RRMS. Also, it aims to evaluate the preliminary evidence of its efficacy by analyzing outcomes related to…
- Trial name
- NCT06812585
- Testing
- Metformin (Cidophage®), Usual Care
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- German University in Cairo
Multiple Sclerosis
Prognostic Value of Cerebrospinal Fluid Immunoglobulin Free Light Chains in Patients With Multiple Sclerosis
Multiple sclerosis (MS) is a chronic inflammatory autoimmune disease of the central nervous system, usually presenting as clinically isolated syndrome (CIS).
- Trial name
- NCT05072691
- Testing
- CSF immunoglobulin (Ig) free light chains (FLC) dosage
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Francis Corazza
Multiple Sclerosis
Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis
Multiple sclerosis (MS) is a chronic inflammatory disease associated with central nervous system (CNS) demyelination and subsequent axonal degeneration. Multiple sclerosis exhibits an unpredictable and variable clinical course.
- Trial name
- NCT01517282
- Testing
- MOR103
- Where
- 5 sites in Germany, Poland and 1 more
- Volunteers
- 32 people
- Sponsor
- MorphoSys AG
Tuberous Sclerosis, Lymphangioleiomyomatosis
Trial of Efficacy and Safety of Sirolimus in Tuberous Sclerosis and LAM
The purpose of this study is to determine the safety and efficacy of the mTOR inhibitor sirolimus as a treatment for renal angiomyolipomas in patients with tyberous sclerosis complex or sporadic lymphangioleiomyomatosis.
- Trial name
- TESSTAL (NCT00490789)
- Testing
- sirolimus
- Where
- 3 sites in United Kingdom
- Volunteers
- 14 people
- Sponsor
- Cardiff University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.